The degradation product that elutes underneath the parent peak

The single most consequential fact about deamidation is that the isoaspartate product has the same molecular weight as the parent peptide, because the rearrangement moves an atom rather than adding or removing one. A laboratory confirming identity by molecular ion mass alone will report a substantially deamidated preparation as the intended compound. Separation is possible — the isomers usually resolve on a sufficiently shallow reversed-phase gradient, and specialist methods resolve them reliably — but only if the method was designed to look. A twelve-minute generic gradient does not look.

Oxidation, and where the oxidant came from

Methionine oxidises to the sulfoxide and, under harsher conditions, the sulfone. Tryptophan oxidises through a series of products including kynurenine derivatives. Histidine and tyrosine are susceptible under metal-catalysed conditions, and free cysteine oxidises readily to disulphide. Each of these products differs from the parent by a defined mass increment, which makes oxidation the pathway most reliably detected by mass spectrometry: the sulfoxide is sixteen mass units heavier and unmistakable.

The interesting question is usually where the oxidant came from, and the answers are mundane. Trace transition metals leached from glass, stainless steel or a stopper catalyse oxidation of several residues. Peroxides accumulate in polysorbate surfactants during storage and are a well-documented source of methionine oxidation in formulated products. Dissolved oxygen in the diluent contributes. Light drives it, particularly for tryptophan, and light exposure during handling is entirely undocumented in this trade.

Practical consequences follow that are not obvious. A formulation containing a surfactant that has itself been stored warm for a year may oxidise a peptide that would have been perfectly stable in a plain aqueous vehicle. Headspace composition matters: vials backfilled with nitrogen behave differently from vials sealed under air, and the difference is a manufacturing choice recorded nowhere on the label.¹

Aggregation, and the method that dissolves the evidence

Aggregation covers a range of species from soluble dimers to visible particles, formed by covalent routes such as disulphide scrambling or by non-covalent association of partially unfolded monomers. For peptides the process is often nucleated at an interface — the air-water interface of a shaken vial, the silicone oil layer on a siliconised stopper, the ice-water interface formed during freezing — which is why mechanical handling and freeze-thaw cycling matter as much as temperature.

The analytical difficulty is severe and specific to the trade’s chosen method. Reversed-phase chromatography runs in an acidic, partly organic mobile phase which dissociates most non-covalent aggregates before or during separation. The aggregate is loaded and the monomer is detected. Size-exclusion chromatography under non-denaturing conditions separates by hydrodynamic volume and reports high molecular weight species directly; analytical ultracentrifugation and light scattering methods characterise them further. None of these is offered as a routine service to this market.

The consequence for a reader is that the aggregate content of a research vial is, at present, an unmeasured quantity. It is not necessarily a large one — well-made lyophilised peptides are frequently very low in aggregate — but no certificate in circulation addresses it, and the purity figure that is printed instead is generated by the one method guaranteed not to see it.²

Hydrolysis, isomerisation and the slower routes

Backbone hydrolysis cleaves an amide bond outright and produces two fragments, each of which is a distinct chromatographic species and each of which is detectable by mass. It is generally slower than deamidation at ordinary storage conditions but becomes dominant at low pH and elevated temperature, which is one reason accelerated stability data for peptides extrapolates so poorly: the pathway that dominates at forty degrees may be irrelevant at five.

Certain positions are much more labile than others. Aspartate-proline and aspartate-glycine bonds hydrolyse relatively readily under acidic conditions. N-terminal glutamine can cyclise to pyroglutamate, losing ammonia. Peptides with an N-terminal sequence of the right geometry can form a diketopiperazine and shed the first two residues as a cyclic dipeptide, a route that is fast enough at neutral pH to matter for some sequences.

Racemisation at susceptible residues produces epimers that are chemically identical in composition and differ only in stereochemistry. They are among the hardest impurities to detect, requiring either a chiral method or a sufficiently discriminating reversed-phase separation, and they are essentially never reported. A vial can be nominally pure by every measurement on its certificate and contain a percentage of a diastereomer with unknown biological behaviour.

What makes a method stability-indicating

A stability study is only as good as the analytical method behind it, and the requirement has a name: the method must be stability-indicating, meaning it must resolve the parent compound from its degradation products and quantify the change. Establishing that is done by forced degradation — deliberately stressing the material with acid, base, oxidant, heat and light — and demonstrating that the resulting products are separated from the parent and from each other with adequate peak purity.

Almost nothing sold as a purity determination in this market has been validated that way. A generic peptide gradient run for twelve minutes may perfectly well resolve the parent from its two largest process impurities and entirely fail to resolve it from its isoaspartate isomer or a closely related oxidation product. The number it returns is a purity figure, not a stability measurement, and using a series of such figures to argue that a product has not degraded is a category error.

The compendial guidance on analytical validation is explicit about specificity, and about demonstrating it against the degradation products the molecule can actually form. The gap between that expectation and practice in this trade is not a matter of dishonesty. It is that the method being sold was designed for a different purpose and is being asked a question it was not built to answer.³

Why accelerated data extrapolates badly for peptides

The temptation with any stability programme is to run the accelerated condition, fit an Arrhenius relationship to the rate constants, and extrapolate to the intended storage temperature. For a single reaction with a temperature-independent mechanism that is sound. For peptides it frequently is not, and the reason is that different pathways have different activation energies.

Suppose a peptide degrades at five degrees principally by deamidation and at forty degrees principally by hydrolysis, with the second having a higher activation energy. Measuring total degradation at forty degrees measures mostly hydrolysis; extrapolating that rate down to five degrees predicts almost nothing about the deamidation that will actually dominate. Aggregation is worse still, because it is frequently nucleated by interfaces and mechanical stress rather than by thermal energy alone, and does not obey a simple temperature relationship at all.

The practical rule the Journal applies when reading a stability claim is to ask what condition the data was generated at and whether the degradation products were identified as well as quantified. Accelerated data that shows which products form is genuinely useful as a warning of what to watch for. Accelerated data reduced to a single percentage and extrapolated to a shelf life is a projection dressed as a measurement, and for this class of molecule it is a poor projection.

Light, and the exposure nobody records

Photostability has its own guideline, its own defined light source options and its own exposure requirement expressed in lux hours of visible light and watt hours per square metre of near ultraviolet. Products are tested in the immediate container, and where they fail, in the marketing pack, and where they fail again the label carries a protection instruction. The chemistry is real: tryptophan and tyrosine absorb in the near ultraviolet and photo-oxidise, and photolytic disulphide cleavage is well documented.

Nothing about light exposure is recorded anywhere in the research-peptide supply chain. Vials are frequently supplied in clear glass. Photographs for listings are taken under studio lighting. Parcels are opened on kitchen counters. A reconstituted vial may sit on a shelf under a window for weeks. The cumulative exposure is unknown and unknowable, and it is plausibly a larger contributor to degradation than the transit excursions that attract all the attention.

The Journal makes one narrow observation rather than a recommendation, because recommendations are not this publication’s business. Amber glass, or a secondary carton, costs a fraction of a cent per unit and removes an uncontrolled variable entirely. Several of the twenty companies we track already ship in amber vials; most do not, and the ones that do not have not, as far as we can establish, generated any data suggesting it does not matter.⁴

The customs leg remains the part of this story we cannot report properly, and it deserves saying every time the subject comes up: there is a segment of every cross-border journey during which nobody measures and nobody has authority to intervene. Any claim of end-to-end control across that segment is a claim about something unobserved.